ENHANCEMENT OF THE ANTILEUKEMIC ACTIVITY OF 5-AZA-2'-DEOXYCYTIDINE BY CYCLOPENTENYL CYTOSINE IN HL-60 LEUKEMIC-CELLS

被引:12
作者
BOUFFARD, DY
MOMPARLER, LF
MOMPARLER, RL
机构
[1] UNIV MONTREAL,DEPT PHARMACOL,MONTREAL H3T 1C5,PQ,CANADA
[2] HOP ST JUSTINE,CTR RECH PEDIAT,MONTREAL H3T 1C5,PQ,CANADA
关键词
5-AZA-2'-DEOXYCYTIDINE; CYCLOPENTENYL CYTOSINE; HL-60; LEUKEMIC CELLS;
D O I
10.1097/00001813-199404000-00014
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We have investigated the capacity of cyclopentenyl cytosine (CPE-C), a potent inhibitor of CTP synthetase, to modulate the antineoplastic activity of 5-aza-2'-deoxycytidine (DAC) on HL-60 myeloid leukemic cells. The combination of CPE-C and DAC produced an additive effect on the growth inhibition of the cells following a treatment of 48-96 h. Cytotoxicity experiments measured by the cloning of cells in soft agar following 24 and 48 h exposures produced a more than additive effect when the drugs were used in combination. Evaluation of the effect of CPE-C and DAC on the induction of differentiation of HL-60 cells following a 48 h treatment revealed that the combination of the drugs produced a more than additive effect than when the drugs were used alone. Measurement of the intracellular pool of deoxycytidine triphosphate (dCTP) showed that a 6 h exposure to 0.05 and 0.1 mu M of CPE-C reduced the pool by 60 and 88%, respectively. The decrease in the dCTP pool was correlated with a higher incorporation of radioactive DAC into DNA. The deamination of CPE-C to cyclopentenyl uridine by cytidine deaminase was investigated with the purified enzyme from human placenta. We report here that CPE-C is a very poor substrate for cytidine deaminase as compared with cytidine. These studies suggest that CPE-C could be used as a biochemical modulator to increase the antileukemic action of DAC.
引用
收藏
页码:223 / 228
页数:6
相关论文
共 30 条
[1]  
BLANEY S, 1991, Proceedings of the American Association for Cancer Research Annual Meeting, V32, P361
[2]  
BLANEY SM, 1992, CANCER RES, V52, P3503
[3]  
BLANEY SM, 1990, CANCER RES, V50, P7915
[4]  
BOUCHARD J, 1983, MOL PHARMACOL, V24, P109
[5]   PURIFICATION AND PROPERTIES OF CYTIDINE DEAMINASE FROM NORMAL AND LEUKEMIC GRANULOCYTES [J].
CHABNER, BA ;
JOHNS, DG ;
COLEMAN, CN ;
DRAKE, JC ;
EVANS, WH .
JOURNAL OF CLINICAL INVESTIGATION, 1974, 53 (03) :922-931
[6]   KINETICS OF DEAMINATION OF 5-AZA-2'-DEOXYCYTIDINE AND CYTOSINE-ARABINOSIDE BY HUMAN-LIVER CYTIDINE DEAMINASE AND ITS INHIBITION BY 3-DEAZAURIDINE, THYMIDINE OR URACIL ARABINOSIDE [J].
CHABOT, GG ;
BOUCHARD, J ;
MOMPARLER, RL .
BIOCHEMICAL PHARMACOLOGY, 1983, 32 (07) :1327-1328
[7]  
DECHATELET LR, 1976, BLOOD, V47, P545
[8]  
DRISCOLL JS, 1987, P AM ASSOC CANC RES, V28, P328
[9]  
FORD H, 1991, CANCER RES, V51, P3733
[10]   INDUCTION OF DIFFERENTIATION IN THE HUMAN PROMYELOCYTIC LEUKEMIA-CELL LINE HL-60 BY THE CYCLOPENTENYL ANALOG OF CYTIDINE [J].
GLAZER, RI ;
COHEN, MB ;
HARTMAN, KD ;
KNODE, MC ;
LIM, MI ;
MARQUEZ, VE .
BIOCHEMICAL PHARMACOLOGY, 1986, 35 (11) :1841-1848